Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06171386 · ClinicalTrials.gov registry record · NA

Microneedling vs Dermabrasion for Early Facial Scar Resurfacing

A NA study of Scar, sponsored by Wake Forest University Health Sciences.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06171386 is a NA study of Scar that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 30 participants, below the 47-participant average among 15 other Scar trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06171386, a NA study of Scar, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study aims to determine whether microneedling or dermabrasion in the early post-operative period is superior in improving the appearance of surgical scars on the face.

Conditions Studied

Interventions

  • PROCEDURE Microneedling
  • PROCEDURE Dermabrasion

Study Locations (1)

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-04-01
Est. Completion 2026-04
Phase NA

Sponsor

Wake Forest University Health Sciences

1,140 total trials

What the Registry Record Tells You About NCT06171386

The ClinicalTrials.gov registry entry for NCT06171386 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47-participant average among 15 other Scar trials with a reported enrollment target (36% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Scar appearing as the primary indexed condition, and to 2 interventions - of which Microneedling is the first listed.

NCT06171386 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT06171386 about?

NCT06171386 is a clinical study titled "Microneedling vs Dermabrasion for Early Facial Scar Resurfacing". This study aims to determine whether microneedling or dermabrasion in the early post-operative period is superior in improving the appearance of surgical scars on the face.

What is the current status of trial NCT06171386?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-04-01. Estimated completion is 2026-04.

What conditions does trial NCT06171386 study?

This clinical trial studies the following conditions: Scar.

What interventions are being tested in trial NCT06171386?

The interventions under investigation include: Microneedling (PROCEDURE), Dermabrasion (PROCEDURE).

Who is sponsoring clinical trial NCT06171386?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06171386 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Scar

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.